50
Participants
Start Date
November 1, 2025
Primary Completion Date
June 30, 2028
Study Completion Date
June 30, 2029
To Measure levels of circulating monocyte/ T cell doublets at Baseline
To determine the levels of circulating monocyte/ T cell doublets on all the LCPOTS subjects
To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment
Subjects will be randomized 1:1 to 2-HOBA or matching placebo. The levels of circulating monocyte/ T cell doublets (immune burden) after 28 days of 2 HOBA treatment
To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment
The levels of circulating monocyte/ T cell doublets (immune burden) after 28 days of 2 HOBA treatment and compare it to the placebo arms
To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA
We will Measure changes in Splanchnic venous capacitance after 28 days of Treatment with 2HOBA and compare it with baseline during 30 Mins head up tilt . All the LCPOTS subjects will be randomized 1:1 to 2-HOBA or matching placebo
To Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo
We will Measure changes in splanchnic venous capacitance during 30 mins head up tilt ,after 28 days of Treatment with Placebo, we will compare it to the subjects who received 2 HOBA for 28 days
To Measure Orthostatic Tachycardia after 28 days of Treatment with 2HOBA
To Measure changes in Orthostatic Tachycardia after 28 days of Treatment with 2HOBA at 30 minutes of head up Tilt
To Measure Orthostatic Tachycardia after 28 days of Treatment with Placebo
To Measure changes in Orthostatic Tachycardia after 28 days of Treatment with Placebo at 30 minutes of head up Tilt and compare it with the subjects who received 28 days of 2HOBA
American Heart Association
OTHER
Vanderbilt University Medical Center
OTHER